68Ga-AAZTA-NI-093 PET/CT: First-in-human Study

Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · Sep 22, 2024

Keywords

ClinConnect Summary

This clinical trial is testing a new imaging tool called 68Ga-AAZTA-NI-093, which is designed to help doctors see prostate cancer more clearly using a type of scan called PET/CT. The study aims to understand how safe this new tool is, how it spreads in the body, how much radiation it uses, and how well it can help in diagnosing prostate cancer. It’s an early-stage trial, meaning it’s one of the first times this tool is being tested in people.

To participate, men aged between 65 and 74 years with treated or untreated prostate cancer are eligible, as long as they can provide consent to join the study. However, individuals with a known allergy to PSMA (the target of the imaging tool) or those with certain medical conditions that might affect their ability to follow the study's requirements won’t be able to participate. If you decide to join, you can expect to undergo some scans and tests to see how well this new imaging tool works for detecting prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • confirmed treated or untreated prostate cancer patients;
• • signed written consent.
• Exclusion Criteria:
• • known allergy against PSMA;
• • any medical condition that in the opinion of the investigator may significantly interfere with study compliance.